Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 85 Dan Rd CANTON MA 02021-2810 |
Tel: | N/A |
Website: | https://investors.organogenesis.com |
IR: | See website |
Key People | ||
Gary S. Gillheeney President, Chief Executive Officer, Director | David C. Francisco Chief Financial Officer | Patrick Bilbo Chief Operating Officer |
Lori Freedman Chief Administrative and Legal Officer | Antonio S. Montecalvo Vice President - Health Policy | Brian Grow Chief Commercial Officer |
Business Overview |
Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting. |
Financial Overview |
For the fiscal year ended 31 December 2023, Organogenesis Holdings Inc revenues decreased 4% to $433.1M. Net income decreased 68% to $4.9M. Revenues reflect Advanced Wound Care segment decrease of 4% to $405.5M, Surgical & Sports Medicine segment decrease of 4% to $27.6M. Net income also reflects Research and development increase of 12% to $44.4M (expense). |
Employees: | 862 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $342.77M as of Dec 31, 2023 |
Annual revenue (TTM): | $433.14M as of Dec 31, 2023 |
EBITDA (TTM): | $35.17M as of Dec 31, 2023 |
Net annual income (TTM): | $4.95M as of Dec 31, 2023 |
Free cash flow (TTM): | $6.55M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 131,963,176 as of Feb 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |